Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia. - Test2 - elhamkhani - TriplyDB

Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.

Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q34008593

about

Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL c Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: a systematic reappraisal of classic cytogenetic data.The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature.Azacitidine in fludarabine-refractory chronic lymphocytic leukemia: a phase II study.Update on chronic lymphocytic leukemia: overview of new agents and comparative analysis.A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL.Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome.Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies?Prophylaxis and Treatment of Pneumocystis jiroveci Pneumonia in Lymphoma Patients Subjected to Rituximab-Contained Therapy: A Systemic Review and Meta-Analysis.Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes.Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis.Relationship between progression-free survival and overall survival in chronic lymphocytic leukemia: a literature-based analysis.State-of-the-Art Management of Patients Suffering from Chronic Lymphocytic Leukemia.Therapeutic advancement of chronic lymphocytic leukemia.Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.New insights into biology, prognostic factors, and current therapeutic strategies in chronic lymphocytic leukemia.What do we do with chronic lymphocytic leukemia with 17p deletion?The role of chemotherapy in managing chronic lymphocytic leukemia: optimizing combinations with targeted therapy.A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53.Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE study.Platinum and high-dose cytarabine-based regimens are efficient in ultra high/high-risk chronic lymphocytic leukemia and Richter's syndrome: results of a French retrospective multicenter study.Infectious complications in chronic lymphocytic leukemia.Outcomes in critically ill chronic lymphocytic leukemia patients.Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemia

P2860

Q30408922-605C26E8-F13B-4874-9CF3-B78EFFCBA248 Q30685440-4E58D39D-D4DD-4E5E-9AE6-A28969193136 Q31033615-B9EC0B4F-E740-45C2-AB56-D37104CA820D Q33404975-46CB4F41-BCF4-454D-914F-088FA9FAD289 Q33406478-C4ACC49E-7170-4003-8613-6193643FB1CD Q33591830-199C445E-E67D-4ABE-B194-478E15743C55 Q34269186-58BD2AA8-4F7B-4481-99FD-2417B774A6CC Q34625543-7DD56DA0-B205-4F3B-872A-E83FD9625A11 Q35613669-52D213A2-7FE7-475E-B12C-7B14FFC16834 Q35625192-7FE42B60-A31B-47BC-971C-C175CD24C258 Q35679601-7DC8B09C-E8B8-441C-A68C-3EF1CF015737 Q35714606-B99FF7C6-60D6-49A7-9636-DB7EE63694C4 Q35860550-6888CCCF-0B86-412C-9351-9D172AF90002 Q36300303-E6B19192-FF47-4114-B450-509B3535A027 Q36768605-E352923B-BCFA-4A7E-9509-0DC323531931 Q36892621-FE58AE42-91DF-42E9-BFD4-279591B00822 Q37147789-F4D52D2E-EF45-47D3-800A-A3F879AE0D75 Q38063170-DC0B4DC8-1132-4A7B-B01E-D74E0D1B680E Q38126946-F3EEEC17-3CEB-499C-9261-3BB4CF5BD5DD Q38231432-2A72B02B-FE24-4332-B23A-CB73049ED3ED Q40303819-10052B69-77FA-48BC-8BC2-0C15D56A987B Q41682806-DEB1B5E4-6239-4D7F-AE25-09D6B393C4A2 Q42277456-9F40D4DA-AFE4-432C-BA87-02B42E7F9200 Q44413722-BD895AC6-EDB6-4FAB-AD54-8D17C7E5832C Q57821050-F30C481D-EEA9-46B1-9205-2F4925FD7D80

P2860

Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q34008593

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

name

Cyclophosphamide, fludarabine, ...... chronic lymphocytic leukemia.

@ast

Cyclophosphamide, fludarabine, ...... chronic lymphocytic leukemia.

@en

Cyclophosphamide, fludarabine, ...... chronic lymphocytic leukemia.

@nl

type

label

Cyclophosphamide, fludarabine, ...... chronic lymphocytic leukemia.

@ast

Cyclophosphamide, fludarabine, ...... chronic lymphocytic leukemia.

@en

Cyclophosphamide, fludarabine, ...... chronic lymphocytic leukemia.

@nl

prefLabel

Cyclophosphamide, fludarabine, ...... chronic lymphocytic leukemia.

@ast

Cyclophosphamide, fludarabine, ...... chronic lymphocytic leukemia.

@en

Cyclophosphamide, fludarabine, ...... chronic lymphocytic leukemia.

@nl

P1433

Q34008593-9C1A06E7-B41A-4664-8100-1F5C22BC2531

P1476

Q34008593-72FD0431-9739-4D72-8721-C09EF0819CE9

P2093

Q34008593-435F07BF-9A6D-4859-AEFB-196D5A94B053

Q34008593-6310A744-0E6D-4D75-8AC6-5E03139EC61A

Q34008593-99695C5A-3A78-4F16-8A56-DDB75CCE9DE1

Q34008593-AAB4EAB5-643C-4962-9420-195FCB85D36C

Q34008593-C1320ECB-6A21-457C-B114-B4DDD1B30657

P2860

Q34008593-053C1447-D084-4784-888E-B4EE0433556B

Q34008593-11BD9D8C-FAB4-4564-9D64-9F7BC5E18EC2

Q34008593-2014CC63-77DE-4665-B0F3-9D5DB05CA48B

Q34008593-2EC017C8-4C7F-43D8-8A10-95E7A0B9518B

Q34008593-33E4FD17-C57D-4981-B3D9-B13FC35EAC3F

Q34008593-3718401F-0FE4-47D5-A551-687A8F8BAB11

Q34008593-3BB831D2-A12C-4D93-B59D-BEFB6CF4BD02

Q34008593-44B9E510-0FB6-44AC-928B-330219F3634A

Q34008593-49C01FDB-2312-4F22-97D1-D07B72785BF4

Q34008593-50E001DF-57C5-4142-8894-1B30E7EF3B1A

P304

Q34008593-2391CF3F-EB95-4221-8708-2994ADC71C64

P31

Q34008593-AABD7268-5DC0-4980-805F-A25FCD261175

P356

Q34008593-6AF0519F-135E-4328-A601-7B9E4884EDD6

P407

Q34008593-58A4EC40-36ED-4D96-9B55-F7C520A87604

P433

Q34008593-769E0A01-A6CC-41AA-9DF9-6B63CED1DBC1

P478

Q34008593-0F901E31-2E79-4643-83CC-6E49704DB92E

P50

Q34008593-29B9F1C0-3876-42A1-84F4-DCBFE37733F8

Q34008593-8408A7A3-1DCD-4FEB-A931-C68979EDBE61

Q34008593-96D08E42-7EE9-43CE-A8B0-B916C455805C

Q34008593-A251D5BB-24A9-4CE8-BE25-7690BF096243

Q34008593-A50FAEE2-3004-4CFE-B672-51A930966275

Q34008593-D95F3BEB-7744-46A1-8269-27373E2DADFA

P577

Q34008593-382198D4-D96D-4CB0-A2E3-201ECE424269

P5875

Q34008593-F10E4E81-540A-403C-93C0-50B1A80B8A5F

P698

Q34008593-0AB4F1AD-AABA-4C73-821D-1B073E6E7D74

P921

Q34008593-422C6FA4-1A96-46FF-A8EB-B6DEB69EC789

Q34008593-5582F965-C156-4BCC-B072-C14F6559BFF1

P932

Q34008593-D80B2100-86E9-4FD2-998A-D44F3B2254A9

P356

BLOOD-2011-03-341032

P1433

P1476

Cyclophosphamide, fludarabine, ...... chronic lymphocytic leukemia.

@en

P2093

Charles Koller

http://www.w3.org/2001/XMLSchema#string

Jan Burger

http://www.w3.org/2001/XMLSchema#string

Susan M O'Brien

http://www.w3.org/2001/XMLSchema#string

Xavier C Badoux

http://www.w3.org/2001/XMLSchema#string

Xuemei Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.

Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.

How I treat CLL up front.

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.

Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab.

Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence.

P304

2085-2093

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2011-03-341032

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P50

Hagop Kantarjian

Alessandra Ferrajoli

William G Wierda

Michael J. Keating

P577

2011-06-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51216574

http://www.w3.org/2001/XMLSchema#string

P698

21670470

http://www.w3.org/2001/XMLSchema#string

P921

P932

4123326

http://www.w3.org/2001/XMLSchema#string